Table 3.
Variable | OR | 24 weeks | OR | 48 weeks |
---|---|---|---|---|
Baseline ART regimen | ||||
NNRTI | 0.72 | 0.31–1.65 | 1.03 | 0.40–2.63 |
Baseline viral load | ||||
<100,000 | 0.57 | 0.24–1.38 | 0.81 | 0.32–2.09 |
Baseline CD4+ count | ||||
<100 | 1.97 | 0.74–5.29 | 3.53 | 1.30–9.56b |
Gender | ||||
Female | 7.38 | 2.25–24.17c | 2.20 | 0.69–7.08 |
Age | ||||
<50 | 1.82 | 0.56–5.93 | 0.99 | 0.24–4.06 |
Ethnicity | ||||
African American | — | — | — | — |
White | 0.76 | 0.23–2.56 | 0.34 | 0.09–1.29 |
Black African | 0.09 | 0.02–0.45c | 0.23 | 0.06–0.97d |
Latino | 7.57 | 1.14–50.13b | 2.02 | 0.33–12.3 |
Adherence | ||||
100–90% | 0.91 | 0.39–2.15 | 1.39 | 0.54–3.58 |
Education | ||||
High school or higher education | 4.98 | 1.01–24.70d | 1.55 | 0.31–7.78 |
NNRTI, nonnucleoside reverse transcriptase inhibitor; ART, antiretroviral treatment.
Significant at 0.01.
Significant at 0.001.
Significant at 0.05.